Cost-utility analysis, the pearl in the crown.
Brown
Melissa M
MM
Brown
Gary C
GC
D000911:Antibodies, Monoclonal / Q000191:economics*; D061067:Antibodies, Monoclonal, Humanized; D002170:Canada; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy / Q000191:economics*; D019057:Quality-Adjusted Life Years; D000069579:Ranibizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab